Achieve Life Sciences to Present at Upcoming Healthcare Conference
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a pioneering specialty pharmaceutical company dedicated to the global development of cytisinicline for nicotine dependence, is gearing up for a significant presentation at a renowned healthcare conference. The Barclays 27th Annual Global Healthcare Conference is set to take place in Miami, offering Achieve a platform to showcase its groundbreaking efforts in smoking cessation.
Details of the Presentation
Rick Stewart, the Chief Executive Officer of Achieve, will take the stage on March 12 at 11:30 AM EDT. This event provides an excellent opportunity for Achieve Life Sciences to share insights about its innovative approaches to combating nicotine addiction. Attendees can expect to learn about the company's latest developments and future directions.
Status of Cytisinicline Development
Achieve Life Sciences is making strides in the fight against nicotine addiction by developing cytisinicline. This plant-based compound has shown promise in clinical trials as an effective treatment for smoking and vaping cessation. The company has successfully completed two Phase 3 trials and is actively pursuing regulatory approval to bring this crucial treatment to market.
Achievements in Research
Cytisinicline has been demonstrated to aid in alleviating nicotine cravings and reducing withdrawal symptoms by targeting the nicotinic acetylcholine receptors in the brain. Achieve Life Sciences has fully enrolled an ongoing open-label safety study for cytisinicline and plans to submit a New Drug Application for smoking cessation in the second quarter of 2025.
Importance of Smoking Cessation
The public health crisis surrounding tobacco use continues to escalate. With approximately 29 million adults in the United States smoking and millions more relying on e-cigarettes, the need for effective cessation therapies has never been more urgent. Tobacco remains the leading cause of preventable death, contributing to over eight million deaths globally each year.
Cytisinicline's Role in Vaping Cessation
As vaping becomes more prevalent, the landscape of nicotine dependence is evolving. Achieve Life Sciences recognizes this shift and has received Breakthrough Therapy designation from the FDA for cytisinicline to specifically target e-cigarette smoking cessation. This highlights the urgency in addressing nicotine addiction in all forms.
Future Prospects for Achieve Life Sciences
Looking forward, Achieve aims to fill a significant gap in treatment options for smokers and vapers. The company has established a robust clinical development program that promises to deliver innovative solutions for nicotine dependence. With its research efforts, Achieve is poised to make substantial contributions to public health by potentially reducing smoking rates and improving lives.
Providing Support for Quitters
In addition to focusing on their clinical advancements, Achieve Life Sciences continually advocates for support systems for individuals looking to quit smoking. Education on the dangers of nicotine addiction alongside effective treatment options is essential for those on the path to recovery.
Engagement with Investors and the Public
Achieve Life Sciences emphasizes transparency and engagement with investors and the public. The upcoming conference provides a perfect venue for sharing progress and garnering support as the company navigates the complexities of drug development and commercialization.
Frequently Asked Questions
What is cytisinicline?
Cytisinicline is a plant-based compound aimed at assisting individuals in overcoming nicotine addiction through its action on nicotine receptors in the brain.
When will Achieve Life Sciences submit its New Drug Application?
Achieve aims to submit its New Drug Application for smoking cessation in the second quarter of 2025.
Who is presenting at the Barclays conference?
Rick Stewart, the CEO of Achieve Life Sciences, will present at the conference.
Why is cytisinicline important for e-cigarette users?
Cytisinicline addresses the growing need for cessation therapies specifically tailored for e-cigarette users, as no FDA-approved options currently exist.
How can I reach Achieve Life Sciences?
For inquiries, you can contact Achieve Life Sciences at ir@achievelifesciences.com or call 425-686-1510.
